Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

NCT01648101 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
76
Enrollment
INDUSTRY
Sponsor class

Stopped Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam

Conditions

Interventions

Sponsor

GlaxoSmithKline